Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities
Net loss	$ (8,041,372)	$ (4,995,376)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	368,102	343,218
Loss on disposal of property and equipment	1,213	0
Stock-based compensation expense	776,994	511,457
Stock issued for services	135,000	0
Write off of deferred financing costs	86,736	0
Amortization of debt discount	218,394	0
Loss on deconsolidation of biologistex	2,785,910	0
Amortization of deferred rent related to lease incentives	(126,997)	(126,999)
Accretion and amortization on available for sale investments	1,792	90,125
(Increase) Decrease in
Accounts receivable, trade	(264,357)	(27,666)
Inventories	(290,838)	(869,411)
Prepaid expenses and other current assets	73,255	15,192
Increase (Decrease) in
Accounts payable	233,482	194,386
Accrued compensation and other current liabilities	(410,151)	(145,419)
Accrued interest, related party	97,857	0
Deferred rent	27,989	36,632
Net cash used in operating activities	(4,326,991)	(4,973,861)
Cash flows from investing activities
Purchase of available-for-sale investments	0	(1,409,695)
Sales/maturities of available-for-sale investments	1,650,000	7,067,000
Costs associated with internal use software development	(1,113,675)	(1,283,685)
Purchase of property and equipment	(143,533)	(134,012)
Net cash provided by investing activities	392,792	4,239,608
Cash flows from financing activities
Proceeds from note payable to related party	3,000,000	0
Proceeds from exercise of common stock options and warrants	278,503	368,753
Deferred costs related to potential stock issuance	(111,736)	0
Net cash provided by financing activities	3,166,767	368,753
Net decrease in cash and cash equivalents	(767,432)	(365,500)
Cash and cash equivalents - beginning of year	2,173,258	2,538,758
Cash and cash equivalents - end of year	1,405,826	2,173,258
Non-cash investing and financing activities
Costs incurred for capitalized internal use software not paid as of year-end (amounts are included in liabilities)	0	415,050
Proceeds from issuance of common stock on exercise of common stock options not received as of year-end	0	32,223
Debt discount related to warrants	374,390	0
Deferred costs related to stock issuance not yet paid	$ 26,975	$ 0